CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 200 enrolled
Drug / intervention
Ocrelizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02980042
NCT02980042Phase 3Completed
CompareCT.gov

Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis

University of Colorado, Denver·interventional·Posted Dec 2, 2016·Updated Jul 21, 2021

In Brief

A Phase 3 clinical trial evaluating Ocrelizumab and Rituximab for Multiple Sclerosis. Completed, enrolled 200 participants across 1 site.

Detailed Summary

This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least two infusions of rituximab, six months apart and are willing to be switched to ocrelizumab compared to a 100 patients who are continuing on rituximab as a comparison cohort from the clinic population treated as part of clinical care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2, 2016
Enrollment StartJan 1, 2017
Primary CompletionMar 6, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.6 years ago

Interventions

Ocrelizumabdrug

A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells

Rituximabdrug

A chimeric monoclonal antibody against CD20.